Topline Trader Is Your Best Shot at Lightning-Fast Triple-Digit Returns

Dear New Technology and Opportunity Member,

I want to thank you again for joining our community of like-minded investors. I'm looking forward to sharing with you the latest plays on mainstream and under-the-radar tech companies that could double or triple your money.

Rest assured that, as a Technology and Opportunity member, you'll get a continuous stream of solid investment opportunities over the course of your subscription. But if you have the stomach to take on a little more risk, then read on...

You see, we'll cover countless tech companies in Technology and Opportunity that offer a solid track record — companies that should be on the short lists of every buy-and-hold investor.

These stocks are poised to provide investors like you with substantial returns over the long run. But they're only the tip of the iceberg when it comes to the kinds of opportunities that my team and I uncover every week.

You see, the truth is that, behind the scenes, we consider Technology and Opportunity to be an introductory investment newsletter. It's where our members can get their toes wet but not where serious traders make their killings.

That designation, where traders can make their killings, is reserved for an exclusive biotech-trading service I run called Topline Trader.

Our strategy at Topline Trader is simple: We identify major catalyst events in drug development and position ourselves to profit from the wild price swings that follow.

You see, it's no secret that when it comes to small, development-stage biotech companies, all you need is a single event to send share prices flying.

FDA decisions, licensing deals, regulatory filings, and — you guessed it — top-line data can have an enormous impact on small biotech stocks. In many cases, we're looking at double- or even triple-digit swings within a matter of hours — even minutes — of these kinds of events.

Gains like...

One-month gains of 192% on ProQR Therapeutics (NASDAQ: PRQR):

[Performance chart embedded in original]

Or a 492% return on Amarin Corporation (NASDAQ: AMRN) in just a few short weeks:

[Performance chart embedded in original]

Or this one-month return of 91% on Viking Therapeutics (NASDAQ: VKTX):

[Performance chart embedded in original]

Not to mention an incredible 1,000% return on Aquinox (NASDAQ: AQPX) in just two weeks of trading:

[Performance chart embedded in original]

Simply put, there's no other sector of the market that allows traders to reliably predict these kinds of major stock swings. In the world of biotechs and pharmaceuticals, it happens on a regular basis.

Our Strategy, and the Benefit to You

At Topline Trader, we focus on small stocks and on major catalyst events that have the potential to move stocks by at least double-digit or triple-digit percentages.

But we don't only provide our members with an organized calendar of events and trading opportunities: We also give them a magic number so they'll have a big leg up on the rest of the market.

We call this magic number our chance of success (CoS). And at any given point in a drug development trial, we can use CoS to tell how likely it is that the drug will be approved.

How We Do It

Topline Trader is made possible not only by our team of dedicated stock analysts but also by an international network of scientists and doctors whose sole purpose it is to track and analyze drug development for us.

This network of over 250 professionals is at the beck and call of our analysts — 24 hours a day, 7 days a week. Every one of them has a Ph.D. diploma hanging on their walls, most have M.D. degrees, and many are even former bench scientists.

And most importantly, this team knows how to read through and make sense of the data in ways the average investor never could. Using a sophisticated algorithm, based on everything from drug category to the Food and Drug Administration (FDA) decision history, they provide us with everything we need to generate our magic CoS number.

As you might expect, access to this network isn't cheap. We pay tens of thousands of dollars for these connections every year. But the good news is that our members don't have to dish out even close to that amount...

What You'll Get

With Topline Trader, we strive to provide our community with unmatched value. With your membership, you'll have exclusive access to a long list of benefits. These include...

• Our interactive FDA and drug development calendar.
• Weekly biotech catalyst alerts.
• Weekly biotech stock analysis.
• Regular trade recommendations.
• Detailed analysis of drug development trials.
• CoS numbers on every drug candidate we cover.
• CoS numbers for any active drug trial and biotech company you request.
• Detailed, easy-to-digest coverage on stocks and drug trials.
• Our full library of company reports.
• Options trading strategies to maximize your leverage.

Due to the timing of catalyst events, our frequency of trading isn't set in stone. But you should expect at least two trading opportunities a month.

And if you join today, you'll be covered by Angel Publishing's no-questions-asked refund for a full 90 days. That means you can use Topline Trader every day for 90 days. And if within those 90 days you find that this service isn't for you, just give us a call. We'll give you a full refund.

Of course, when you see the outsize returns that you could make from each recommendation, I'm certain you'll stick around.

Now, quite frankly, I could charge hedge funds and professional traders $5,000 or even more for what I'm sending you today, and it would still be a steal.

But you won't pay that much or anything close to that amount...

In fact, as a new member of Technology and Opportunity, you can get a one-year subscription to Topline Trader today for only $999. That's a massive discount on our standard retail price of $4,999. And it comes with a full 90-day money-back guarantee.

Frankly, that's the best offer you'll ever get for this exclusive trading service. But there's a catch...

I can only offer this deal to you once. So, when you leave this page, you'll never see it again.

Truth be told, I shouldn't give this level of research, analysis, and opportunity away for "pennies on the dollar." My publisher hates it when we go this low...

But I know that biotech is the place to be for quick, killer returns. And I want to give you the opportunity to grow wealthier alongside me without having to dig deep into your pocket.

So, if you want a front-row seat to the most lucrative biotech opportunities this year, at a fraction of what you'd otherwise pay annually, click the button below to get started.

Again, you're covered by Angel Publishing's 90-day money-back guarantee. So, you have nothing to lose and everything to gain.

To your wealth,

Jason Stutman
Investment Director, Technology and Opportunity and Topline Trader